e-Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2021

Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). (#221)

Jayesh Desai 1 , Scott Kopetz 2 , Dan Aderka 3 , Axel Grothey 4 , Eric Van Cutsem 5 , Rona Yaeger 6 , Harpreet Singh Wasan 7 , Takayuki Yoshino 8 , Fortunato Ciardiello 9 , Lorraine Chantrill 10 , Niall Tebbutt 11 , Andrew Strickland 12 , Timothy Price 13 , Chris Karapetis 14 , Felicity Murphy 15 , Ashwin Gollerkeri 16 , Adele Golden 16 , Michelle L Edwards 16 , Josep Tabernero 17
  1. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  2. MD Anderson Cancer Center, Houston, TX
  3. Sheba Medical Center, Tel-Hashomer, Israel
  4. West Cancer Center, OneOncology, Germantown, TN
  5. University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium
  6. Memorial Sloan Kettering Cancer Center, New York, NY
  7. Hammersmith Hospital, Division of Cancer, Imperial College London, London, United Kingdom
  8. National Cancer Center Hospital East, Kashiwa, Japan
  9. University of Campania Luigi Vanvitelli , Naples, Italy
  10. St Vincent’s Hospital, Sydney, NSW, Australia
  11. Austin Health – Medical Oncology, Melbourne, VIC, Australia
  12. Monash Health and Monash University, Melbourne, VIC, Australia
  13. Medical Oncology Unit, Queen Elizabeth Hospital and University of Adelaide, Adelaide, South Australia, Australia
  14. Flinders Medical Centre and Flinders University, Adelaide, SA, Australia
  15. The Mater Hospital, Brisbane, QLD, Australia
  16. Pfizer, New York, NY
  17. Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain

Background: Enco + cetux (doublet) has been approved in the US, EU, and Japan for the treatment of BRAF V600E-mutant mCRC after progression on 1–2 prior regimens. In the BEACON CRC study (NCT02928224), median OS (95% CI) with the doublet was 9.3 months (8.0–11.3) vs 5.9 months (5.1–7.1) with cetux + irinotecan or FOLFIRI (control) in patients (pts) with BRAF V600E-mutant mCRC (HR 0.61 [95% CI: 0.5–0.8]). This post-hoc analysis investigates OS by prior therapies to the doublet treatment in pts with BRAF V600E-mutant mCRC from the BEACON CRC study.

Methods: OS of pts treated with the doublet or control were compared according to prior treatment with bevacizumab, oxaliplatin, or FOLFOXIRI and duration of prior anticancer therapy (ACT).

Results: 64% and 55% of pts in the doublet and control arm respectively received prior bevacizumab. Of pts who had one prior therapy, 95% and 88% received prior oxaliplatin and 20% and 14% received prior FOLFOXIRI, respectively. In the doublet arm, pts who had bevacizumab < 4 months before start of study treatment had a median OS of 8.3 months (95% CI: 6.2–11.2); those who had bevacizumab ≥4 months prior had a median OS of 10.7 (95% CI: 7.5–17.7). Within each treatment arm, OS was similar regardless of prior treatment with oxaliplatin or FOLFOXIRI. The duration of prior ACT was similar across study arms, ranging from 5.6–5.8 months for the first line of ACT.

Conclusions: In the BEACON CRC study, pts treated with the doublet for BRAF V600E-mutant mCRC demonstrated similar OS regardless of prior therapies or duration of prior therapy use. This exploratory post-hoc analysis provides data that reflect the prior treatment landscape clinicians may face when deciding subsequent treatment regimens for pts with BRAF V600E-mutant mCRC. Clinical trial information: NCT02928224.